For many years scientists and industry alike have been working to harness the power of the cells for the purpose of restoring and regenerating body systems that have been damaged by disease or injury. This is one of the reasons that drives the researchers of Advanced Cell Technology, (ACT) Inc to study that resulted panels of differentiating human progenitor cell lines from human embryonic stem cell. The research will be published in the April issue of Regenerative Medicine (Vol. 3(3). The ACT Cellerate technologies very likely hasten the translation of human embryonic stem cell-based therapies into safe and effective products for routine clinical practice.

Experts have termed it as a major development in research work. The ACT scientists are excited over the whole issue. The benefits of the ACT Cellerate technology transcend therapeutics and extend as well into revolutionary applications for drug discovery, drug toxicity testing, and cancer research. This research holds great promise for future study and may one day lead to many new cell-based therapies in the emerging field of regenerative medicine, believe experts. Another important finding in this research is that these normal embryonic progenitor cell types show the expression of certain genes often associated in the literature with malignant cancer.
Source:FOX BUSINESS